Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3163-3165

  Madrigal, Andres G ^a   Basuino, Li ^a   Chambers, Henry F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; METICILLIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AORTA VALVE; AORTA VALVE DISEASE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; AORTIC VALVE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HEART VALVE DISEASES; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 23044488583     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3163-3165.2005     Document Type: Article

References (10)

1. Chambers, H. F. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin- Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888.
2. Climo, M. W., R. L. Patron, and G. L. Archer. 1999. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob. Agents Chemother. 43: 1747-1753.
3. Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J. P. Shaw, G. Obedencio, and J. K. Judice. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48: 3043-3050.
4. Higgins, D. L., R. Chang, D. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. Hubbard, K. Kaniga, D. E. Schmidt Jr., Q. Gao, R. T. Cass, D. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 49:1127-1134.
5. Judice, J. K., and J. L. Pace. 2003. Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. 13:4165-4168.
6. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
7. Pace, J. L., K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D. L. Higgins, B. Christensen, J. K. Judice, and K. Kaniga. 2003. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3602-3604.
8. Shaw, J. P., Seroogy, J., K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
9. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, S. K. McAllister, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
10. Van Bambeke, F. 2004. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4:471-478.